Test Your GA GPA! Challenge 3 - Current and Emerging Treatments
Activity Description and Purpose
This educational activity will review the pathophysiology of geographic atrophy and the clinical data for currently available geographic atrophy treatments.
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Describe the pathophysiology of geographic atrophy as it relates to disease management
- Review clinical trial data for therapy that targets complement for geographic atrophy
Faculty
Ashkan M. Abbey, MD, FASRS, FAAO
|
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Ashkan M. Abbey, MD, is a consultant for Allergan, EyePoint Pharmaceuticals, and Genentech, Inc; is on the speakers bureau for Alimera Sciences, Allergan, Apellis Pharmaceuticals, Biogen Idec, Coherus Biosciences, Genentech, Inc, Iveric Bio, Inc, and Regeneron Pharmaceuticals, Inc; and is a contracted researcher for EyePoint Pharmaceuticals.
Peer Reviewers
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Iveric Bio, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Iveric Bio, Inc.
©2023 MedEdicus LLC. 296.2c
Available Credit
- 0.25 AMA PRA Category 1 Credit™
- 0.25 Participation